Tango Therapeutics - TNGX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.67
  • Forecasted Upside: 41.12%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.81
▲ +0.01 (0.08%)

This chart shows the closing price for TNGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tango Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNGX

Analyst Price Target is $16.67
▲ +41.12% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Tango Therapeutics in the last 3 months. The average price target is $16.67, with a high forecast of $18.00 and a low forecast of $16.00. The average price target represents a 41.12% upside from the last price of $11.81.

This chart shows the closing price for TNGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Tango Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2024Piper SandlerInitiated CoverageOverweight$18.00Low
12/8/2023B. RileyInitiated CoverageBuy$16.00Low
8/11/2023HC WainwrightBoost Target$11.00 ➝ $16.00Low
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
3/28/2023HC WainwrightBoost TargetBuy$10.00 ➝ $11.00Low
11/16/2022WedbushBoost Target$21.00Low
10/20/2022HC WainwrightUpgradeNeutral ➝ BuyLow
9/20/2021SVB LeerinkInitiated CoverageOutperformHigh
9/7/2021WedbushInitiated CoverageOutperformHigh
9/7/2021GuggenheimInitiated CoverageBuy$16.00High
9/7/2021The Goldman Sachs GroupInitiated CoverageBuy$17.00High
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/2/2023
  • 1 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/1/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/30/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/29/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Tango Therapeutics logo
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $11.81
Low: $11.67
High: $11.97

50 Day Range

MA: $11.15
Low: $9.18
High: $12.88

52 Week Range

Now: $11.81
Low: $2.47
High: $13.03

Volume

15,313 shs

Average Volume

645,712 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Tango Therapeutics?

The following Wall Street research analysts have issued stock ratings on Tango Therapeutics in the last twelve months: B. Riley, HC Wainwright, and Piper Sandler.
View the latest analyst ratings for TNGX.

What is the current price target for Tango Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Tango Therapeutics in the last year. Their average twelve-month price target is $16.67, suggesting a possible upside of 41.1%. Piper Sandler has the highest price target set, predicting TNGX will reach $18.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $16.00 for Tango Therapeutics in the next year.
View the latest price targets for TNGX.

What is the current consensus analyst rating for Tango Therapeutics?

Tango Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNGX will outperform the market and that investors should add to their positions of Tango Therapeutics.
View the latest ratings for TNGX.

What other companies compete with Tango Therapeutics?

How do I contact Tango Therapeutics' investor relations team?

Tango Therapeutics' physical mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company's listed phone number is 857-320-4900 and its investor relations email address is [email protected]. The official website for Tango Therapeutics is www.tangotx.com. Learn More about contacing Tango Therapeutics investor relations.